![]() | This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Allopurinol.
|
Fixed a few problems:
StormWillLaugh ( talk) 10:59, 4 March 2010 (UTC)
The formula is incorrect.
This is the correct formula :
http://www.uft.uni-bremen.de/chemie/SAR-Buch/jpg/allopurinol.gif —Preceding unsigned comment added by NennMichMeister ( talk • contribs) 20:47, 12 September 2010 (UTC)
While on the whole this article is quite well written, there are number of factual errors, and it requires updating. I am doing this, as well as adding refs for new parts and missing citations. - JD 8 Sep 12 — Preceding unsigned comment added by Johnaduley ( talk • contribs) 13:35, 8 September 2012 (UTC) Edit completed Johnaduley ( talk) 14:36, 8 September 2012 (UTC)
The text says Elion invented allopurinol as a cancer drug metabolism inhibitor. Wrong. Elion tried it for that, but took the drug off the shelf as an already known molecule. Elion does not claim otherwise in the cited Nobel lecture. Allopurinol was first synthesized and reported by Roland K. Robins (1926-1992) an old mentor of mine. The ref is R. K. Robins, J. Amer. Chem. Soc.,78, 784 (1956). S B H arris 15:27, 24 April 2013 (UTC)
What does this mean?
"Allopurinol can be used in patients with poor kidney function, but it may also help them."
It certainly is poor wording but I can't change it without knowing more. Maybe "can be used... and may even improve kidney function"? Arbalest Mike ( talk) 23:24, 26 April 2014 (UTC)
Stern RJ.
Editor's Note: Reducing Life-Threatening Allopurinol Hypersensitivity
http://archinte.jamanetwork.com/article.aspx?articleID=2397728
JAMA Intern Med. Published online July 20, 2015.
doi:10.1001/jamainternmed.2015.3546
Yang C, Chen C, Deng S, et al.
Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.
http://archinte.jamanetwork.com/article.aspx?articleID=2397733
JAMA Intern Med. Online July 20, 2015.
doi:10.1001/jamainternmed.2015.3536.
This study was in Taiwan, with a 95% Han Chinese population, with high incidence of HLA-B*5801 and 4 times the incidence of allopurinol hypersensitivity syndrome as the U.S. In Taiwan, the mortality among new users was 0.39/1,000 and the incidence of hypersensitivity was 4.68/1,000. Renal and cardiovascular disease are risk factors. -- Nbauman ( talk) 02:40, 24 July 2015 (UTC)
Per the tag, this should be sourced better and restored:
![]() | This section needs more
reliable medical references for
verification or relies too heavily on
primary sources. (September 2015) | ![]() |
Allopurinol can be used in patients with poor kidney function. A study of allopurinol use in patients with chronic kidney disease suggested, "Allopurinol decreases C-reactive protein and slows the progression of renal disease in patients with chronic kidney disease. In addition, it reduces cardiovascular and hospitalization risk in these subjects." [1]
A mechanistic study in patients with chronic heart failure has shown the actions of allopurinol may be due to its inhibition of xanthine oxidase rather than a urate-lowering effect. This study also showed, for the first time, a high dose (600 mg) is significantly better at improving endothelial function compared to standard doses. [2]
A recent study has suggested allopurinol may help reduce the effects of angina in ischaemic heart disease by reducing the workload on the heart. [3]
Allopurinol can decrease blood pressure, thus reducing hypertension. [4]
References
{{
cite journal}}
: Unknown parameter |laydate=
ignored (
help); Unknown parameter |laysource=
ignored (
help); Unknown parameter |laysummary=
ignored (
help)
-- Jytdog ( talk) 06:42, 29 August 2016 (UTC)
How long should you take allapurinol 2600:1005:B053:CF2C:8D1A:960A:881F:2292 ( talk) 00:14, 13 July 2022 (UTC)
![]() | This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Allopurinol.
|
Fixed a few problems:
StormWillLaugh ( talk) 10:59, 4 March 2010 (UTC)
The formula is incorrect.
This is the correct formula :
http://www.uft.uni-bremen.de/chemie/SAR-Buch/jpg/allopurinol.gif —Preceding unsigned comment added by NennMichMeister ( talk • contribs) 20:47, 12 September 2010 (UTC)
While on the whole this article is quite well written, there are number of factual errors, and it requires updating. I am doing this, as well as adding refs for new parts and missing citations. - JD 8 Sep 12 — Preceding unsigned comment added by Johnaduley ( talk • contribs) 13:35, 8 September 2012 (UTC) Edit completed Johnaduley ( talk) 14:36, 8 September 2012 (UTC)
The text says Elion invented allopurinol as a cancer drug metabolism inhibitor. Wrong. Elion tried it for that, but took the drug off the shelf as an already known molecule. Elion does not claim otherwise in the cited Nobel lecture. Allopurinol was first synthesized and reported by Roland K. Robins (1926-1992) an old mentor of mine. The ref is R. K. Robins, J. Amer. Chem. Soc.,78, 784 (1956). S B H arris 15:27, 24 April 2013 (UTC)
What does this mean?
"Allopurinol can be used in patients with poor kidney function, but it may also help them."
It certainly is poor wording but I can't change it without knowing more. Maybe "can be used... and may even improve kidney function"? Arbalest Mike ( talk) 23:24, 26 April 2014 (UTC)
Stern RJ.
Editor's Note: Reducing Life-Threatening Allopurinol Hypersensitivity
http://archinte.jamanetwork.com/article.aspx?articleID=2397728
JAMA Intern Med. Published online July 20, 2015.
doi:10.1001/jamainternmed.2015.3546
Yang C, Chen C, Deng S, et al.
Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.
http://archinte.jamanetwork.com/article.aspx?articleID=2397733
JAMA Intern Med. Online July 20, 2015.
doi:10.1001/jamainternmed.2015.3536.
This study was in Taiwan, with a 95% Han Chinese population, with high incidence of HLA-B*5801 and 4 times the incidence of allopurinol hypersensitivity syndrome as the U.S. In Taiwan, the mortality among new users was 0.39/1,000 and the incidence of hypersensitivity was 4.68/1,000. Renal and cardiovascular disease are risk factors. -- Nbauman ( talk) 02:40, 24 July 2015 (UTC)
Per the tag, this should be sourced better and restored:
![]() | This section needs more
reliable medical references for
verification or relies too heavily on
primary sources. (September 2015) | ![]() |
Allopurinol can be used in patients with poor kidney function. A study of allopurinol use in patients with chronic kidney disease suggested, "Allopurinol decreases C-reactive protein and slows the progression of renal disease in patients with chronic kidney disease. In addition, it reduces cardiovascular and hospitalization risk in these subjects." [1]
A mechanistic study in patients with chronic heart failure has shown the actions of allopurinol may be due to its inhibition of xanthine oxidase rather than a urate-lowering effect. This study also showed, for the first time, a high dose (600 mg) is significantly better at improving endothelial function compared to standard doses. [2]
A recent study has suggested allopurinol may help reduce the effects of angina in ischaemic heart disease by reducing the workload on the heart. [3]
Allopurinol can decrease blood pressure, thus reducing hypertension. [4]
References
{{
cite journal}}
: Unknown parameter |laydate=
ignored (
help); Unknown parameter |laysource=
ignored (
help); Unknown parameter |laysummary=
ignored (
help)
-- Jytdog ( talk) 06:42, 29 August 2016 (UTC)
How long should you take allapurinol 2600:1005:B053:CF2C:8D1A:960A:881F:2292 ( talk) 00:14, 13 July 2022 (UTC)